Benchmark Maintains Buy on Exact Sciences, Lowers Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson maintains a Buy rating on Exact Sciences (NASDAQ:EXAS) but lowers the price target from $91 to $67.

August 01, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Benchmark analyst Bruce Jackson maintains a Buy rating on Exact Sciences but lowers the price target from $91 to $67.
The Buy rating suggests continued confidence in the company's long-term prospects, but the lowered price target indicates a more cautious short-term outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100